Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,995,669
  • Shares Outstanding, K 132,376
  • Annual Sales, $ 1,095 M
  • Annual Income, $ 528,580 K
  • 60-Month Beta -0.55
  • Price/Sales 2.49
  • Price/Cash Flow 5.06
  • Price/Book 1.89
Trade VIR with:

Options Overview Details

View History
  • Implied Volatility 84.23% ( -8.01%)
  • Historical Volatility 84.27%
  • IV Percentile 16%
  • IV Rank 26.05%
  • IV High 112.12% on 08/18/21
  • IV Low 74.41% on 10/22/21
  • Put/Call Vol Ratio 0.10
  • Today's Volume 55
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 11,322
  • Open Int (30-Day) 10,900

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate 0.09
  • Low Estimate -0.19
  • Prior Year 0.46
  • Growth Rate Est. (year over year) -110.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.21 +22.35%
on 05/12/22
23.80 -6.39%
on 04/18/22
-1.65 (-6.90%)
since 04/14/22
3-Month
18.21 +22.35%
on 05/12/22
32.44 -31.32%
on 02/17/22
-10.63 (-32.30%)
since 02/16/22
52-Week
18.21 +22.35%
on 05/12/22
58.00 -61.59%
on 12/20/21
-19.93 (-47.22%)
since 05/14/21

Most Recent Stories

More News
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VIR : 22.28 (-1.55%)
BLI : 4.77 (-8.45%)
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results

– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and...

VIR : 22.28 (-1.55%)
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

ENDP : 1.1500 (-4.17%)
VRTX : 254.17 (+3.02%)
ZTS : 165.50 (+0.10%)
NTLA : 45.96 (-5.43%)
VIR : 22.28 (-1.55%)
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales

Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.

GSK : 44.37 (+2.42%)
JNJ : 178.08 (+0.70%)
PFE : 50.67 (+1.50%)
VIR : 22.28 (-1.55%)
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today,...

VIR : 22.28 (-1.55%)
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?

Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.

GSK : 44.37 (+2.42%)
GILD : 62.24 (-0.21%)
VRTX : 254.17 (+3.02%)
VIR : 22.28 (-1.55%)
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022

SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and...

VIR : 22.28 (-1.55%)
4 Undervalued Biotech Stocks to Add to Your Buy List

Biotech stocks are defensives that could be just what the doctor ordered for the market's current uncertain conditions

DNLI : 23.27 (+1.79%)
RCUS : 19.79 (+2.17%)
VIR : 22.28 (-1.55%)
GSK : 44.37 (+2.42%)
BNTX : 151.20 (-4.81%)
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months

Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.

REGN : 655.01 (+1.47%)
GSK : 44.37 (+2.42%)
LLY : 299.38 (+2.66%)
VIR : 22.28 (-1.55%)
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis...

VIR : 22.28 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 24.67
2nd Resistance Point 24.10
1st Resistance Point 23.19
Last Price 22.28
1st Support Level 21.71
2nd Support Level 21.14
3rd Support Level 20.23

See More

52-Week High 58.00
Fibonacci 61.8% 42.80
Fibonacci 50% 38.10
Fibonacci 38.2% 33.41
Last Price 22.28
52-Week Low 18.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar